
IHH Healthcare in transformation and expansion mode
On the inorganic growth front, the group is on the lookout for strategic acquisitions, including hospitals in Malaysia, India and Turkiye.
Group CEO Dr Prem Kumar Nair said while underperforming assets in China represent only a small fraction of IHH's overall portfolio, they have recently shown signs of improvement.
'In fact, the group remains optimistic about its prospects in China and is set to invest in a major ambulatory care centre in Shanghai,' he told reporters after the company's annual general meeting today.
Dr Prem said what is particularly significant at this stage is the recognition that IHH must undergo – a comprehensive transformation to achieve many of its strategic goals.
'As a well-established organisation, some of our hospitals have been serving communities for decades – Punggol East in Singapore, Gleneagles with a 65-year legacy, Mount Elizabeth approaching 50 years, as well as Gleneagles Penang and Pantai Hospital Kuala Lumpur, both with over half a century of service.
'Given this legacy, we are now shifting our focus towards key transformation areas.
'One of the most important is the introduction of a new care model, which we have already begun implementing in markets like Singapore and Hong Kong. We are also actively encouraging other countries within our network to adopt this forward-looking approach to healthcare delivery,' Dr Prem said.
The group's revenue in FY24 increased 16% to RM24.4 billion, and earnings before interest, taxes, depreciation and amortisation) stood at RM5.4 billion, a 17% growth from FY23.
Profit after tax and minority Interest (Patmi) declined 10% to RM2.7 billion, mainly due to the one-off gain from the disposal of the International Medical University in 2023. Excluding extraordinary items, Patmi grew 32% from a year ago to RM1.7 billion.
Return-on-equity (ROE) growth remains a key focus, and on the back of the strong financial performance, IHH declared a total of 10 sen per share in ordinary dividends in FY24, an increase from 9 sen per share in FY23.
'Many have asked whether factors like tariffs and geopolitical uncertainty – including developments in Turkiye and the US presidency of Donald Trump – have had an impact on us.
'Despite these external challenges, we have demonstrated strong resilience, delivering double-digit revenue and profit growth and achieving an ROE of 9%, edging closer to our target of double-digit ROE,' Dr Prem said.
He said IHH's success is defined by meeting or exceeding a comprehensive set of indicators for each value-driven care procedure.
Currently, the group is tracking eight high-volume procedures under this framework – including total knee replacement, colonoscopy, and breast cancer – monitoring over 360 indicators every month. These procedures account for about 20% of all inpatient admissions across the network, representing a significant portion of patient care and clinical activity.
'By next year, we plan to expand this programme to include two additional procedures, such as Caesarean sections, allowing more patients to benefit from outcome-driven care.
'To achieve and elevate the level of quality we aim for, we are making strategic investments in cutting-edge medical equipment and improved infrastructure,' Dr Prem said.
As a group, he pointed out, IHH reinvests its profits into clinical research, quality improvement programmes and innovations aimed at enhancing patient outcomes.
The company has embraced technology-driven care, such as ProtonBeam therapy for cancer treatment, and is creating seamless digital experiences to elevate service quality, including through the MyHealth360 app, which gives patients direct access to their healthcare.
Equally important, Dr Prem said, IHH is committed to empowering both patients and staff by investing in continuous learning, development and modern work tools to enable its people to deliver exceptional care and perform at their best.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New Straits Times
an hour ago
- New Straits Times
Health Ministry, IHH Healthcare ink MoU to expand free cancer treatment for 500 patients
PUTRAJAYA: The Health Ministry (MOH) and IHH Healthcare Malaysia signed their third Memorandum of Understanding (MoU) today, aimed at strengthening a strategic public-private partnership to improve access to advanced cancer treatment. Health Minister Datuk Seri Dr Dzulkefly Ahmad said the agreement will enable an additional 500 cancer patients to receive high-quality radiotherapy and radiosurgery at no cost, through services delivered by MOH oncologists and neurosurgeons via IHH's facilities. "This agreement also brings the total number of participating IHH facilities to eight hospitals, including the newly added Island Hospital in Penang, which are equipped with Gamma Knife and LINAC technologies allowing for precise, high-impact treatment, especially for tumours located in sensitive areas," he said after the MoU signing ceremony. The MoU was signed by MOH secretary-general Datuk Seri Suriani Ahmad and IHH Healthcare Malaysia chief executive officer Jean-François Naa. Dzulkefly said the collaboration, first established in 2022, has benefited 1,000 cancer patients nationwide so far. "This collaboration is a concrete step toward closing the access gap for underserved and lower-income groups. It also reflects Malaysia's broader commitment to Universal Health Coverage, where cancer care is not treated as a privilege but as a right. "We should never allow a patient's health outcome to be dictated by where they live or how much they earn," he said. Dzulkefly said from 2020 to 2024, the Malaysia National Cancer Registry recorded more than 165,000 new cancer cases, with breast, colorectal, lung, lymphoma and liver cancer being the most common. "Alarmingly, over 60 per cent of cases are detected at late stages, when treatment is more complex, costly, and less effective," he said. Meanwhile, according to a statement issued by MOH, the types of cancer treated under the MoU include brain tumours, brain metastases, head and neck cancers, as well as various other cancers such as lung, breast, colorectal and lymphoma. It said the MoU would serve as a catalyst in strengthening public-private partnerships, further supporting the ministry's efforts in combating cancer and expanding access to care and treatment for cancer patients in the country through continued cooperation between the MOH and IHH Healthcare Malaysia. "This initiative is also aligned with the National Strategic Plan for Cancer Control, which prioritises early detection, effective treatment, palliative care and broad system coordination to reduce the national cancer burden," the statement read. — BERNAMA

The Star
an hour ago
- The Star
500 more cancer patients to get free treatment at IHH Healthcare Malaysia hospitals
PUTRAJAYA: An additional 500 cancer patients will receive free treatment at IHH Healthcare Malaysia hospitals starting this month, says Datuk Seri Dr Dzulkefly Ahmad. This positive news comes following the signing of a third memorandum of understanding (MoU) between the ministry and IHH Healthcare Malaysia. The Health Minister revealed that the agreement would bring the total number of participating IHH facilities to 8 hospitals, including the newly added Island Hospital in Penang. Dzukefly said these facilities were equipped with Gamma Knife and LINAC technologies, allowing for precise, high-impact treatment, especially for tumours located in sensitive areas. 'The types of cases available for treatment include brain tumours, brain metastases, head and neck cancers, as well as various other cancers such as lung, breast, colon and lymphoma,' he said in a speech at the MoU signing ceremony here on Monday (July 7). Aimed at expanding access to cancer treatment for patients referred from Health Ministry hospitals, Dzukefly said the MoU signing would serve as a catalyst to strengthening public-private collaboration in the fight against cancer. 'This MoU will continue to support MOH's efforts in tackling cancer while broadening access to cancer care and treatment across the country. 'This collaboration is a concrete step toward closing the access gap for underserved and lower-income groups,' he said, adding that this third MoU will be in effect until January 2027. He also called for sustained commitment from all stakeholders across the healthcare sector to continue helping the Ministry build a system where early detection, advanced treatment, and compassionate support would be available to every patient, everywhere.

Barnama
2 hours ago
- Barnama
MOH, IHH Healthcare Malaysia Ink MoU To Expand Free Cancer Treatment For 500 Patients
PUTRAJAYA, July 7 (Bernama) -- The Health Ministry (MOH) and IHH Healthcare Malaysia signed their third Memorandum of Understanding (MoU) today, aimed at strengthening a strategic public-private partnership to improve access to advanced cancer treatment. Health Minister Datuk Seri Dr Dzulkefly Ahmad said the agreement will enable an additional 500 cancer patients to receive high-quality radiotherapy and radiosurgery at no cost, through services delivered by MOH oncologists and neurosurgeons via IHH's facilities. 'This agreement also brings the total number of participating IHH facilities to eight hospitals, including the newly added Island Hospital in Penang, which are equipped with Gamma Knife and LINAC technologies allowing for precise, high-impact treatment, especially for tumours located in sensitive areas,' he said after the MoU signing ceremony. The MoU was signed by MOH secretary-general Datuk Seri Suriani Ahmad and IHH Healthcare Malaysia chief executive officer Jean-François Naa. Dzulkefly said the collaboration, first established in 2022, has benefited 1,000 cancer patients nationwide so far. 'This collaboration is a concrete step toward closing the access gap for underserved and lower-income groups. It also reflects Malaysia's broader commitment to Universal Health Coverage, where cancer care is not treated as a privilege but as a right. 'We should never allow a patient's health outcome to be dictated by where they live or how much they earn,' he said. Dzulkefly said from 2020 to 2024, the Malaysia National Cancer Registry recorded more than 165,000 new cancer cases, with breast, colorectal, lung, lymphoma and liver cancer being the most common. 'Alarmingly, over 60 per cent of cases are detected at late stages, when treatment is more complex, costly, and less effective,' he said.